Back to School: How biopharma can reboot drug development. Access exclusive analysis here

AIM vs Main

AIM vs Main

Although London's Alternative Investment Market (AIM) is often seen as second tier, weekly share volume has increased since May 2002, albeit in far smaller numbers than on the Main market. So far this year, according

Read the full 378 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers